Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas.
作者信息
Locke Margaret, Kohn Nina, Seetharamu Nagashree
机构信息
Department of Internal Medicine, Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York, USA.
Office of Academic Affairs, Northwell Health, Manhasset, New York, USA.
出版信息
Clin Otolaryngol. 2023 Nov;48(6):915-919. doi: 10.1111/coa.14091. Epub 2023 Jul 30.
PMID:37517814
Abstract
摘要
相似文献
1
Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas.低剂量每周一次紫杉醇、卡铂和西妥昔单抗（PCC）方案治疗转移性或不可切除头颈部鳞状细胞癌的疗效和耐受性
Clin Otolaryngol. 2023 Nov;48(6):915-919. doi: 10.1111/coa.14091. Epub 2023 Jul 30.
2
Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.含卡铂、白蛋白紫杉醇和西妥昔单抗的诱导化疗适用于 N2b 及以上淋巴结状态或不可手术切除的头颈部鳞状细胞癌。
Oral Oncol. 2018 Sep;84:46-51. doi: 10.1016/j.oraloncology.2018.06.028. Epub 2018 Jul 19.
3
Towards risk-stratified induction regimens.迈向风险分层诱导方案。
Nat Rev Clin Oncol. 2019 Apr;16(4):209. doi: 10.1038/s41571-019-0168-6.
4
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).紫杉醇、卡铂和西妥昔单抗联合治疗作为复发性和/或转移性头颈部鳞状细胞癌（CSPOR-HN02）一线治疗的 II 期临床试验。
Ann Oncol. 2018 Apr 1;29(4):1004-1009. doi: 10.1093/annonc/mdy040.
5
Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.紫杉醇、卡铂和西妥昔单抗新辅助化疗治疗局部晚期头颈部鳞状细胞癌的安全性和有效性。
Int J Clin Oncol. 2024 Aug;29(8):1133-1141. doi: 10.1007/s10147-024-02545-9. Epub 2024 May 10.
6
Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.紫杉醇、卡铂和西妥昔单抗诱导化疗治疗不适合多西紫杉醇、顺铂和 5-氟尿嘧啶联合治疗的局部晚期不可切除头颈部癌症患者的疗效和可行性。
Int J Clin Oncol. 2020 Nov;25(11):1914-1920. doi: 10.1007/s10147-020-01742-6. Epub 2020 Jul 9.
7
Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial.西妥昔单抗联合顺铂与紫杉醇单独或联合治疗头颈部鳞状细胞癌患者的疗效和安全性：一项随机试验。
Cancer Control. 2021 Jan-Dec;28:1073274821997444. doi: 10.1177/1073274821997444.
8
Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease.对每周使用紫杉醇、卡铂和西妥昔单抗治疗无法治愈的头颈癌患者的评估。
Med Oncol. 2016 Oct;33(10):107. doi: 10.1007/s12032-016-0822-0. Epub 2016 Aug 27.
9
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.未经治疗的局部晚期头颈部鳞状细胞癌患者，接受每周紫杉醇、卡铂、西妥昔单抗、西妥昔单抗、多烯紫杉醇、顺铂和氟尿嘧啶治疗，随后进行局部治疗。
Ann Oncol. 2019 Mar 1;30(3):471-477. doi: 10.1093/annonc/mdy549.
10
Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.每周多西他赛、顺铂和西妥昔单抗姑息治疗头颈部鳞状细胞癌患者。
Oncologist. 2018 Jul;23(7):764-e86. doi: 10.1634/theoncologist.2017-0618. Epub 2018 Mar 14.
Zotero 插件